Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22831009 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL22831008 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL5221675 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL5221669 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL22492028 | 0.85 | MAPT (0.50) | MEN1ALDH1A1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL22492032 | 0.85 | MAPT (0.50) | MEN1ALDH1A1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL22492027 | 0.85 | MAPT (0.50) | MEN1ALDH1A1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL5216002 | 0.77 | SLC6A3 (0.46) | SLC6A2SLC6A4SLC6A3MAPK1SMN1; SMN2 | |
| SCHEMBL7278537 | 0.77 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5215996 | 0.77 | SLC6A3 (0.46) | SLC6A2SLC6A4SLC6A3MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | LES LABORATOIRES SERVIER (FR) | 2022-05-17 | — | — | US | disclosed |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | LES LABORATOIRES SERVIER (FR) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | USP7, PSMA7, PSMB7 | SLC6A2 4768/4885SLC6A4 4373/4885SLC6A3 4189/4885 |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | PSMB7, PSMA7, USP7 | SLC6A2 4853/4885SLC6A4 4708/4885SLC6A3 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.